HK18695A - Inhalation medicaments for treating respiratory disorders - Google Patents

Inhalation medicaments for treating respiratory disorders Download PDF

Info

Publication number
HK18695A
HK18695A HK18695A HK18695A HK18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A
Authority
HK
Hong Kong
Prior art keywords
respiratory disorders
treating respiratory
inhalation medicaments
inhalation
medicaments
Prior art date
Application number
HK18695A
Other languages
English (en)
Inventor
Barry Douglas Palmer James
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK18695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK18695A publication Critical patent/HK18695A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HK18695A 1989-09-08 1995-02-09 Inhalation medicaments for treating respiratory disorders HK18695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
HK18695A true HK18695A (en) 1995-02-17

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18695A HK18695A (en) 1989-09-08 1995-02-09 Inhalation medicaments for treating respiratory disorders

Country Status (20)

Country Link
EP (1) EP0416951B1 (enExample)
JP (1) JP3042867B2 (enExample)
AT (1) ATE99941T1 (enExample)
BE (1) BE1003053A3 (enExample)
CA (1) CA2024916C (enExample)
CH (1) CH680983C9 (enExample)
DE (2) DE69005951T2 (enExample)
DK (1) DK0416951T3 (enExample)
ES (1) ES2062392T3 (enExample)
FR (1) FR2651677B1 (enExample)
HK (1) HK18695A (enExample)
HU (1) HU211272A9 (enExample)
IE (1) IE65535B1 (enExample)
IL (1) IL95590A (enExample)
IT (1) IT1241996B (enExample)
LU (1) LU90392I2 (enExample)
NL (1) NL990012I2 (enExample)
NZ (1) NZ235221A (enExample)
PH (1) PH27594A (enExample)
SG (1) SG166294G (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
JP3342484B2 (ja) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
ES2298323T3 (es) 1998-11-13 2008-05-16 Jagotec Ag Inhalador de polvo seco multidosis con reserva de polvo.
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
CO5310534A1 (es) * 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1471895B2 (en) 2002-02-04 2012-03-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
CA2508692C (en) 2002-12-12 2012-04-03 Altana Pharma Ag Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
MX2007000592A (es) 2004-07-16 2008-03-04 Almirall Lab Inhalador para la administracion de farmaceuticos en polvo, y un sistema de cartuchos de polvo para uso con este inhalador.
ES2378786T3 (es) 2006-12-22 2012-04-17 Almirall, S.A. Dispositivo de inhalación para fármacos en forma de polvo
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
ES2774367T3 (es) 2009-05-29 2020-07-20 Pearl Therapeutics Inc Composiciones para el suministro respiratorio de agentes activos y métodos y sistemas asociados
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2014177519A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
EP0416951A1 (en) 1991-03-13
NL990012I1 (nl) 1999-07-01
FR2651677B1 (fr) 1993-08-06
DK0416951T3 (da) 1994-02-14
FR2651677A1 (fr) 1991-03-15
HU211272A9 (en) 1995-11-28
ATE99941T1 (de) 1994-01-15
CH680983C9 (enExample) 2008-08-15
IL95590A0 (en) 1991-09-16
NL990012I2 (nl) 1999-09-01
IE65535B1 (en) 1995-11-01
SG166294G (en) 1995-06-16
DE69005951D1 (de) 1994-02-24
CA2024916C (en) 2002-07-09
CH680983A5 (enExample) 1992-12-31
PH27594A (en) 1993-08-31
CA2024916A1 (en) 1991-03-09
IT9048260A0 (it) 1990-09-07
JPH03167120A (ja) 1991-07-19
DE69005951T2 (de) 1994-05-26
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
IT1241996B (it) 1994-02-02
JP3042867B2 (ja) 2000-05-22
IE903256A1 (en) 1991-03-13
CH680983C1 (enExample) 2008-06-25
DE19975040I2 (de) 2006-07-13
IL95590A (en) 1996-06-18
BE1003053A3 (fr) 1991-11-05
NZ235221A (en) 1992-11-25
LU90392I2 (fr) 1999-06-28
EP0416951B1 (en) 1994-01-12

Similar Documents

Publication Publication Date Title
HK18695A (en) Inhalation medicaments for treating respiratory disorders
GB2235626B (en) Inhalation medicaments for treating respiratory disorders
CA2123909A1 (en) New combination of formoterol and budesonide
GEP20002253B (en) Pharmaceutical Aerosol Formulation, Proportioning Inhalator and Method for Treatment of Respiratory Diseases
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
GB9425160D0 (en) Medicaments
CA2125666A1 (en) Medicaments
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
GB9103764D0 (en) Compositions
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
AU3598299A (en) Improved compositions for inhalation
MY111155A (en) Medicaments
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
CA2321265A1 (en) Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070907